OOS, OOT, OOC, and OOSC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

OOS, OOT, OOC, and OOSC
Current GMPs demand full understandng of out-of-control concepts. This article contains bonus material.


Pharmaceutical Technology
Volume 35, Issue 10, pp. 46-47

Out-of-trend

A more recent concern is being out-of-trend (OOT). An OOT situation exists when one or more reportable results, collected over a period of time, are compared with a historical data set or with a statistical model and determined to be different from a practical significance standpoint.

The cause behind OOT occurrences can take several forms. The process could experience a sudden change in the average or have an outlying data point. The standard deviation of the data could increase or decrease. The general direction of the data could be gradually upward or downward, which is often called process drift. Finally, the process could cycle up and down. Cycling can occur if the operators over control for the critical process parameters (also known as independent variables or factors) and actually induce additional variability into the critical quality attributes (also known as dependent variables or responses). Note that OOT is usually perceived as a negative event but it could be a positive one. If the variability decreases or if the average moves towards the target, that would be a beneficial trend. If stability data does not change over the course of the study, that would be a neutral trend. These changes need not reach the level of statistical significance to raise an alert and initiate a response.

This concept is supported by the recent Supreme Court case for Matrixx (4, see page 118 for the full report). The court held that a change or difference does not have to be statistically significant to warrant a preliminary examination of the data or even an investigation. Thus, OOT is seen as a practical significance issue and not a statistical one.

The comparison of practical significance and statistical significance was discussed in the March 2010 Statistical Solutions column on the role of statistical significance tests (5). The goal of a statistical significance test is to prevent us from deciding something is important when it is just due to chance. In fact, if a difference or change is not of any practical importance or significance, being statistically significant is frankly not of much interest.

Western Electric 8

The application of statistical concepts to manufacturing in the United States is often traced to 1924 when Dr. Walter Shewhart wrote his famous memo describing for the first time the statistical control chart (or Shewhart chart) while he was working at Western Electric in Cicero, Illinois.

At that time, the term "control" was innocuous enough and didn't raise questions when he and others spoke of control limits and of being OOC. In the context of statistical control charts, if the pattern of values exceeds one or more the Western Electric 8 (WE8) rules, the data set is said to be "out-of-control" (6). (Note that most companies only use one or two, and no more than three, of the eight rules to avoid over-control.) But we need an additional modifier here as well. It is clearer to say the data set or process is "out-of-statistical-control" (OOSC).

This has been the case since 1924, and there is no reason to change such an old habit now. If someone speaks of being out-of-control in the context of a statistical control chart we assume it is out-of-statistical-control. It should be pointed out that it is possible to be out-of-statistical-control and still always meet the specifications.

Not all processes, for example biotechnology, will easily exist in a consistent state of statistical control. Such a situation is often called being in a "state of engineering control." In the chemical and refining industries, engineering control is more narrowly defined as the application of proportional, integral, or derivative tuners for process control.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here